NCI-MCI WORKSHOP

Molecular Brain Imaging in Very Early Alzheimer's disease

Auditorium 1, Rigshospitalet, Copenhagen University Hospital

Thursday February 2nd, 2006

10:00-10:20 **Welcome**
Gitte Moos Knudsen, The Neurobiology Research Unit, The Neuroscience Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

SESSION 1: Progression in MCI

Chairperson: Gunhild Waldemar

10:20-11:00 Predictive accuracy of MCI subtypes for Alzheimer's disease. Data from longitudinal studies.
Frans R. J. Verhey, Research Institute Brain and Behavior, Department of Psychiatry and Neuropsychology, University of Maastricht/University Hospital Maastricht, Maastricht, The Netherlands

11:00-11:30 **Coffee**

11:30-12:10 Structural changes associated with progression in MCI.
Jean-Claude Baron, Department of Neurology and Stroke Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom

12:10-12:30 Do patients complain? Anosognosia in MCI and its consequences for clinical criteria.
Asmus Vogel, Memory Disorders Research Unit, The Neuroscience Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

12:30-13:30 **Lunch**

13:30-13:50 The EU Concerted Action: Neuroreceptor Imaging in Mild Cognitive Impairment.
Gitte Moos Knudsen, The Neurobiology Research Unit, The Neuroscience Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

SESSION 2: Microglia Activation in MCI and Alzheimer's disease

Chairperson: Sabina Pappata

13:50-14:30 In vivo imaging of neuroinflammation in degenerative diseases.
Alexander Gerhard, Dep. of Psychiatry, University of Mainz, Mainz, Germany

14:30-15:00 **Coffee**

15:00-15:30 Modelling aspects of [11C](R)-PK11195 PET
Ronald Boellaard, Dep. Nuclear Medicine and PET Research, VU University, Medical Center, Amsterdam, the Netherlands

15:30-16:00 Microglia activation in MCI and AD patients measured using [11C](R)-PK11195 PET.
Alie Schuitemaker, Alzheimer Center, Department of Neurology, VU University, Medical Center, Amsterdam, The Netherlands

16:00-16:40 Neuroinflammation and serotonergic function in early Alzheimer's disease. ***Jan Versijpt*****,** Department of Neurology, Memory Clinic, Antwerp, Belgium

19:00 **Dinner (**restaurant Sankt Gertruds Kloster, Hauser Plads 32, Copenhagen K)

Friday February 3rd, 2006

09:00-09:40 Molecular imaging by magnetic resonance.
Silvio Aime, Department of Chemistry, University of Torino, Torino, Italy.

SESSION 3: The Serotonin System in very early Alzheimer's disease

Chairperson: Gitte Moos Knudsen

09:40-10:10 PET determination of regional cerebral 5-HT1A receptor binding in AD and matched controls.
Patrik Mattsson**,** Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institute, Stockholm, Sweden.

10:10-10:40 Serotonin 2A receptor binding in MCI studied with PET and [18F]-altanserin. ***Steen G. Hasselbalch***, The Neurobiology Research Unit, The Neuroscience Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

10:40-11:10 **Coffee**

SESSION 4: Beta-amyloid imaging

Chairperson: Claus Svarer

11:10-11:50 Beta-amyloid imaging: methodological aspects.
Julie C. Price, Dept. of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

11:50-12:20 Beta-amyloid imaging in MCI.
Agneta Nordberg, Neurotec Department, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

12:20-13:20 **Lunch**

SESSION 5: Metabolism, Blood Flow, and the GABA system

Chairperson: Olaf Paulson

13:20-14:00 Functional Relevance of changes in acetylcholine esterase activity and glucose metabolism.
Karl Herholz**,** Manchester Molecular Imaging Centre, Manchester, United Kingdom

14:00-14:30 GABA-A benzodiazepine receptor changes in AD and MCI patients assessed with SPET and iomazenil.
Sabina Pappata**,** Biostructure and Bioimaging Institute, National Research Council, Naples, Italy.

14:30-15:00 Future collaboration. The Diagnostic Molecular Imaging (DiMI) Network of Excellence
Gitte Moos Knudsen and Karl Herholz